Targeting CD44 by CRISPR-Cas9 in Multi-Drug Resistant Osteosarcoma Cells

Conclusion: CD44 silencing could inhibit the development of osteosarcoma migration, invasion, proliferation and ameliorate drug resistance to current treatment in osteosarcoma. This study applies new strategy to target CD44, which may improve the prognosis of osteosarcoma.Cell Physiol Biochem 2018;51:1879 –1893

https://www.karger.com/Article/FullText/495714

Source: Cellular Physiology and Biochemistry - November 30, 2018 Category: Cytology Source Type: research